Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuraxisNRXS -1.72%42 Days Payable is 183.34 as of Jun. 2026, which is 68% below its 10-year median of 580.79. GuruFocus rates NRXS with a GF Score™ of 42/100 and a GF Value™ of $3.38 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 703 Biotechnology companies, Neuraxis ranks better than 67.14% on this metric.
Neuraxis's average Accounts Payable for the
three
months ended in Jun. 2026 was $0.55 Mil. Neuraxis's Cost of Goods Sold for the
three
months ended in Jun. 2026 was $0.27 Mil.
Hence, Neuraxis's Days Payable for the
three
months ended in Jun. 2026 was 183.34.
The historical rank and industry rank for Neuraxis's Days Payable or its related term are showing as below:
NRXS'
s Days Payable Range Over the Past 10 Years
Min: 125.21 Med: 580.79 Max: 1684.06
Current: 245.9
During the past 6 years, Neuraxis's highest Days Payable was 1684.06. The lowest was 125.21. And the median was 580.79.
NRXS's Days Payable is ranked better than 67.14% of 703
companies
in the Biotechnology industry
Industry Median: 110.14
vs NRXS: 245.90
Neuraxis's Days Payable
declined
from Jun. 2025 (310.37) to Jun. 2026 (183.34).
It may suggest that Neuraxisaccelerated paying its suppliers.
The historical data trend for Neuraxis's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Neuraxis's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuraxis Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuraxis's Days Payable distribution charts can be found below:
* The bar in red indicates where Neuraxis's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Neuraxis's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuraxis (NRXS) has a Days Payable of 183.34 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neuraxis and its competitors. This is 68% below median its historical median of 580.79. Over the past decade, Neuraxis' Days Payable has ranged from 125.21 to 1,684.06. According to the industry distribution chart, Neuraxis ranks #231 out of 703 companies in the Biotechnology industry, placing it in the top 32.9%.
Is Neuraxis' Days Payable too high?
Neuraxis' current Days Payable of 183.34 is 68% below median its 10-year median of 580.79. Over the past 10 years, this metric has ranged from a low of 125.21 to a high of 1,684.06. The Biotechnology industry median Days Payable is 110.14. Neuraxis' value of 183.34 is 66.5% above this industry median. Based on the distribution chart, Neuraxis ranks #231 out of 703 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Neuraxis has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuraxis' Days Payable compare to CSBR and RLYB?
According to the Biotechnology industry distribution chart, Neuraxis ranks #231 out of 703 companies for Days Payable. This puts Neuraxis in the upper half of its industry. The industry median Days Payable is 110.14. Neuraxis' value of 183.34 is 66.5% above this benchmark. Historically, Neuraxis' own Days Payable has ranged from 125.21 to 1,684.06 over the past decade. While the company's 10-year median is 580.79 vs. the industry median of 110.14, Neuraxis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.14, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuraxis's current Days Payable of 183.34 is 66.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neuraxis and its competitors. For the Biotechnology industry, the median Days Payable is 110.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuraxis's current Days Payable is 183.34, which is 68% below median its own 10-year median of 580.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuraxis stock overvalued right now?
Based on GuruFocus' analysis, Neuraxis (NRXS) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.38, compared to a current price of $6.27 — trading 85.5% above its estimated fair value. The current Days Payable is 183.34, which is 68% below median its 10-year median of 580.79 and 66.5% above the Biotechnology industry median of 110.14. Neuraxis' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Neuraxis (NRXS), the current Days Payable is 183.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuraxis (NRXS) Overvalued in 2026?
Based on GuruFocus' analysis, Neuraxis stock appears to be overvalued.
The current stock price of $6.27 is trading 85.5% above its estimated GF Value™ of $3.38.
GuruFocus considers Neuraxis to be Significantly Overvalued.
Key valuation signals for NRXS:
Days Payable: 183.34 (68% below median its 10-year median of 580.79)
GF Value™: $3.38 vs. price of $6.27 (85.5% above fair value)
Industry Position: 66.5% above the Biotechnology median (#231 of 703)
No single metric tells the full story. See the NRXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
42GF Score
Get the complete analysis for NRXS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NRXS has been successfully added to your 
